1644 PATENT

Case Docket No. VANMA83.001APC

I hereby certify that this correspondence and

an envelope addressed to: Assistant Commissio

for Patents, Washington, D.C. 20231, on

marked attachments are being deposited with the United States Postal Service as first class mail

Date: March 9, 2000-

1600 MAIL ROOM

\$0

Page 1

In re application of

Communi et al.

App. No.

09/077,183

Filed

November 12, 1998

For

RECEPTOR AND NUCLEIC

ACID MOLECULE ENCODING

SAID RECEPTOR

Examiner

Joseph F. Murphy

Art Unit

1644

ASSISTANT COMMISSIONER FOR PATENTS

WASHINGTON, D.C. 20231

Sir:

Transmitted herewith is a Response to Restriction Requirement in the above-identified application.

The fee has been calculated as shown below:

CLAIMS AS FILED						
,	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA	RATE	ADDITIONAL FEE
Total Claims	21		21	= 0 ×	\$9	= \$0
Independent Claims	4		4	= 0 ×	\$39	= \$0
If application has bee dependent claim(s),		tain multipl	e		\$130	= \$0
Time Extension Fee					-	\$0
			• • •	TOTAL ADD	ITIONAL F	EE

(X) A small entity status of this application under 37 CFR 1.9 and 1.27 has been established by a verified statement previously submitted.

(X) Return prepaid postcard.

(X) Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410. A duplicate copy of this sheet is enclosed.

Neil S. Bartfeld, Ph.D. Registration No. 39,901 Agent of Record

FOR THIS AMENDMENT

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant

Communi et al.

Group Art Unit 1644

Appl. No.

09/077,183

Filed

November 12, 1998

For

RECEPTOR AND NUCLEIC

ACID MOLECULE

ENCODING SAID RECEPTOR

Examiner

Joseph F. Murphy

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

In response to the Restriction Requirement mailed February 9, 2000, Applicants hereby elect Group I, Claims 70-80, 84 and 89, drawn to a receptor, a polynucleotide encoding the receptor, a vector, a host cell, and a method of compound screening, with traverse.

Although the five claim groups set forth by the Examiner are patentably distinct they contain overlapping subject matter (SEQ ID NO: 2). Therefore, a proper search of Group I would necessarily reveal references directed to Groups II-IV. In addition, the Group III claims (85 and 90) depend on Claims 84 and 89, respectively, which are in Group I. Thus, Group III should not be separated from Group I.

M.P.E.P. §803 states, in part, that "if the search and examination of an entire application can be made without serious burden, the examiner must examine it on the merit, even though it includes claims to independent or distinct inventions." In the present case, Applicants submit that examination of all pending claims would not place such a burden on the Examiner.

Applicants are aware that the Examiner is not bound by findings in the CT application from which the present application entered the U.S. national phase. However, in the PCT case,

RECEIVEL

Appl: No. Filed

77,183

November 12, 1998

69 claims were filed and no lack of unity objection was raised. In the present case, these 69 claims were condensed to 20 claims which cover less subject matter that did the original claims. Accordingly, Applicants submit that the restriction is improper and respectfully request that it be withdrawn.

Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated:

3/9/00

By:

Neil S. Bartfeld, Ph.D. Registration No. 39,901

Agent of Record

620 Newport Center Drive

Sixteenth Floor

Newport Beach, CA 92660

(619) 235-8550

S:\DOC\$\N\$B\N\$B-4118.DOC 030800

